Work

Overcoming MCL-1-driven adaptive resistance to targeted therapies

Year: 2020

Type: article

Abstract: Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.

Source: Nature Communications

DOI: 10.1038/s41467-020-14392-z

Author: Kris C. Wood

Institution: Duke University

Language: English

Topic: Cell death mechanisms and regulation

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,380